SRNE
SORRENTO THERAPEUTICS INC
OTC Link · USD
Stock performance
How SORRENTO THERAPEUTICS INC (SRNE) stock has performed from one day to one year, with its 52-week range.
- 1D
- +0.00%
- 1W
- +0.00%
- 1M
- -40.00%
- YTD
- -88.46%
- 1Y
- -94.55%
- 52-wk range
- $0.00 – $0.01
Key statistics
Today's trading snapshot for SRNE: day range, open, previous close, volume and market cap.
- Day range
- —
- Open
- —
- Prev close
- $0.00
- Volume
- 0
- Market cap
- —
- Shares out
- —
8-K filings
Material corporate events SORRENTO THERAPEUTICS INC has disclosed to the SEC on Form 8-K.
- Voluntary bankruptcyFeb 22, 2023
on February 13, 2023, Sorrento Therapeutics, Inc. ('Sorrento' or the 'Company') and its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc. (together with the Company, the 'Debtors'), commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas
- Delisting determinationFeb 21, 2023
the staff of Nasdaq had determined that the Company's common stock will be delisted from Nasdaq. The Delisting Notice indicated that trading of the Company's common stock will be suspended at the opening of business on February 23, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company's common stock from listing and registration on Nasdaq.
- Material litigationFeb 13, 2023
On December 2, 2022, the arbitrator in that arbitration issued an award (the 'Antibody Award') granting contractual damages and pre-award interest in the amounts of $156,829,562 to NantCell and $16,681,521 to NANTibody. On February 7, 2023, the Court granted the Nant Entities' petitions, entered judgment upon the Antibody Award, and ordered Sorrento to pay to the Nant Entities the previously disclosed amounts awarded in the Antibody Award.
- Material litigationFeb 13, 2023
In April 2019, the Company filed an action in the Los Angeles Superior Court derivatively on behalf of Immunotherapy NANTibody LLC against NantCell, Inc. and Patrick Soon-Shiong, among others, related to several breaches of the June 11, 2015 Limited Liability Company Agreement. The suit alleges breaches of fiduciary duties and seeks restoration of $90.05 million to the NANTibody capital account.
- Voluntary bankruptcyFeb 13, 2023
On February 13, 2023, Sorrento Therapeutics, Inc. (the "Company") and its wholly-owned direct subsidiary, Scintilla Pharmaceuticals, Inc., commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas (the "Chapter 11 Filings").
Dividend history and stock splits
SORRENTO THERAPEUTICS INC's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-25Aug 1, 2013
SRNE short interest
How heavily SRNE is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 29.6
- Short interest
- 3.5M
- Avg volume
- 118.19K
As of · reported to FINRA twice monthly.
SRNE news
The latest news and headlines about SORRENTO THERAPEUTICS INC (SRNE).
- Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common StockpositiveGlobeNewswire Inc.· Oct 29, 2024
- By 2034, CAR-T Cell Therapy Market Set to Soar USD 8.7 Billion, at 1.80% CAGR: Prophecy Market InsightspositiveGlobeNewswire Inc.· Aug 27, 2024
- Why Sorrento Therapeutics Stock Crashed TodayThe Motley Fool· Feb 22, 2023
- Why Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionBenzinga· Feb 22, 2023
- The stock market is due a bounce after the 697-point selloff in the Dow, says this analyst. Here's why. MarketWatch· Feb 22, 2023
Frequently asked questions
What is the SORRENTO THERAPEUTICS INC (SRNE) stock price today?
Massive provides real-time and historical SORRENTO THERAPEUTICS INC (SRNE) quotes via REST API, WebSocket and MCP.
What is SORRENTO THERAPEUTICS INC?
SORRENTO THERAPEUTICS INC
What is the short interest in SRNE?
As of Oct 30, 2026, SRNE has 3.5M shares short and 29.6 days to cover.
What exchange is SRNE listed on?
SORRENTO THERAPEUTICS INC (SRNE) trades on OTC Link in USD.
Build with AI
Build an analysis of SRNE with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a SRNE analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.